Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201104007 Principal Investigator: Vij, Ravi
Title: A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
Phase: I Disease Site: Multiple Myeloma
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu
Description:
The purposes of this study are to:

Determine the highest dose of the drug that can safely be given without unacceptable (intolerable) side effects to subjects who have Multiple Myeloma.

Determine if the study drug might work, to be used in the treatment of MM.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)